Cas:683224-96-6 1-(3-Cyanopropyl)-3-methylimidazolium chloride manufacturer & supplier

Chemical Name:1-(3-Cyanopropyl)-3-methylimidazolium chloride

CAS.NO:683224-96-6

Synonyms:1-(3-Cyanopropyl)-3-methylimidazolium chloride

Molecular Formula:C₈H₁₂ClN₃

Molecular Weight:185.65400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:32.60000

Exact Mass:185.07200

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-(3-Cyanopropyl)-3-methylimidazolium chloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(3-Cyanopropyl)-3-methylimidazolium chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-(3-Cyanopropyl)-3-methylimidazolium chloride Use and application,1-(3-Cyanopropyl)-3-methylimidazolium chloride technical grade,usp/ep/jp grade.

Related News: As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 1-(3-Cyanopropyl)-3-methylimidazolium chloride manufacturer In a statement to Fierce Medtech, Innova said it has completed some corrective actions, while others are still underway, and that the U.S. recall was launched to reclaim tests distributed to employees, clinical studies and to customers for early evaluation. The company said it plans to seek an emergency use authorization and comply with all FDA requirements. 1-(3-Cyanopropyl)-3-methylimidazolium chloride supplier A new case of coronavirus has been reported in the United Arab Emirates, the country’s fifth, the Ministry of Health and Prevention announced on Saturday. 1-(3-Cyanopropyl)-3-methylimidazolium chloride vendor The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace. 1-(3-Cyanopropyl)-3-methylimidazolium chloride factory As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL.